Law Firm in the Netherlands specialised in Pharmaceuticals

Back to Life Sciences & Healthcare

In the last decade, it has become increasingly complex and costly to obtain marketing authorisation. On top of this,  market access has become   more complex and difficult  because of ongoing pressure on national health budgets. Our specialised regulatory team is able to support clients facing these challenges and to help maximising commercial opportunities.

We offer extensive expertise in every phase of developing pharmaceutical products, from R&D activities to clinical trials, from marketing and selling a product to advising on late life cycle activities; for every step we offer accompanying legal advice. We can answer all your questions: whether this is regulatory, anti-corruption, public procurement  or tax related.

We also represent clients in legal proceedings related to price and reimbursement issues involving government decisions and in domestic and cross-border litigation related to commercial disputes, M&A, defending product liability claims, protecting intellectual property rights and code compliance issues.  

Subscribe to Life Sciences & Healthcare topics
Stay up-to-date with our client services.
CMS Expert Guide to advertising of medicines and medical devices
Advertising of pharmaceuticals and medical devices is a challenging area for the Life Sciences and Healthcare industry.The legal framework is constantly changing. Due to very few laws on this area, there are significant differences between jurisdicti


Compulsory licensing in the Netherlands
1. What is the definition of compulsory licensing? There is no specific legal definition for compulsory licensing under Dutch law. However, the Dutch Patents Act 1995 contains a number of requirements...
CMS advises Immatics on the business combination with Arya Sciences Acquisition...
Immatics N.V. has announced the completion of its business combination with Arya Sciences Acquisition Corporation. The Immatics shares and warrants are now traded under the symbol “IMTX” and the...
Podcast: Advertising of Medicines and Medical Devices
The series brings together CMS lawyers and experts to discuss key industry topics impacting, innovating and disrupting the life sciences & healthcare sector.  In Episode #2, Nick Beckett (China/Hong...
CMS Global Life Sciences & Healthcare Forum 2019
 We have the pleasure to cordially invite you to our    on Thursday, 21 November 2019, at 09:30 CET in Frankfurt. The Forum will provide insights from external experts and CMS specialists on four core...
WLG Cannabis Legalization: Europe Update
What is the status of cannabis liberalization in the Netherlands, Germany and Spain? Panelists Ellen Gielen (CMS Netherlands), Jörn Witt, Susanne Pech (both CMS Germany) and Juan Carlos Hernanz (Cuatrecasas...
Ellen Gielen: "Alternatives to expensive medicines: the legal leeway is...
It is very positive that in the Netherlands alternatives to expensive medicines are being considered. But from a legal perspective, the ability to apply the alternatives is limited and little attention...
SYNLAB takes control with testing acquisition
In one of last year’s most significant deals in the life sciences sector, CMS client SYNLAB bought ALcontrol, a European provider of environmental testing services. SYNLAB is Europe’s leading provider...
Moving times
Following Brexit, Britain must pay to relocate the European Medicines Agency from London to a city within the EU and 19 European countries are placing their bids to be the next host. Indeed the EMA is...
Legal developments in product liability
The medical industry is under increasing legal pressure these days owing mainly to a con­sumer-friendly risk environment. This is evident from restrictive legislation and recent landmark cases, such as...
Distribution and marketing of drugs in The Netherlands
Country contribution for the publication "Distribution and Marketing of Drugs Global Guide 2015". This contribution focuses on the distribution and marketing of drugs law in The Netherlands
Taking the Pulse of the Global Life Sciences Industry
The CMS Lifesciences sector group is delighted to provide you with our report on the Global Lifesciences Forum held in Amsterdam on 10 November 2014. The CMS Lifesciences publication is an excellent piece...
The tricky business of drug/device classification in the EU
On 3 October, the Court of Justice of the EU published its long-awaited ruling in the Laboratories Lyocentre case in relation to the classification of medical products. The CJEU ruled that a product can...